Could a diabetes drug boost heart surgery success?

NCT ID NCT07331727

Not yet recruiting Disease control Sponsor: Shanghai Chest Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests whether dapagliflozin, a drug typically used for diabetes, can reduce the return of atrial fibrillation after a heart ablation procedure. The study focuses on patients with persistent AF and increased epicardial adipose tissue (heart fat), which is linked to higher recurrence risk. About 280 participants will receive either dapagliflozin or standard care for 3 months after ablation. The main goal is to see if the drug lowers the amount of time spent in atrial arrhythmia.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dapagliflozin (a diabetes drug that may also reduce heart fat and inflammation)
What this could lead to: If it works, this could offer a new way to improve ablation success in persistent atrial fibrillation patients with excess heart fat.
What could go wrong: This is an early-stage trial with no phase assigned, so results are uncertain. The drug may not reduce recurrence, and side effects like dehydration or urinary infections are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION (AF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation persistent atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATRIAL FIBRILLATION (AF)

Contacts and locations

Locations

Shanghai Chest Hospital

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.